Open AccessReducing mortality in newly diagnosed standard-risk acute promyelocytic leukemia in elderly patients treated with arsenic trioxide requires major reduction of chemotherapy: a report by the French Belgian Swiss APL group (APL 2006 trial)
Author(s) -
Ramy Rahmé,
Lionel Adès,
Xavier Thomas,
Agnès GuerciBresler,
Arnaud Pigneux,
Norbert Vey,
Emmanuel Raffoux,
Sylvie Castaigné,
Olivier Spertini,
Sébastian Wittnebel,
Jean Pierre Marolleau,
Gandhi Damaj,
Dominique Bron,
Julie Lejeune,
Sylvie Chevret,
Pierre Fenaux
Publication year - 2018
Publication title -
haematologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.782
H-Index - 142
eISSN - 1592-8721
pISSN - 0390-6078
DOI - 10.3324/haematol.2018.193151
Subject(s) - arsenic trioxide , acute promyelocytic leukemia , medicine , chemotherapy , pediatrics , oncology , arsenic , retinoic acid , biochemistry , materials science , chemistry , metallurgy , gene